Spero Therapeutics AI Stock Analysis
Spero Therapeutics (2HA) AI Stock Analysis
Spero Therapeutics
(Frankfurt:2HA)
No summary available
Spero Therapeutics (2HA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 58.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,000
- Price to Earnings (P/E)
- 7.1
- Beta (1Y)
- 1.18
- Revenue Growth
- 18.44%
- EPS Growth
- ―
- Country
- Germany
- Employees
- 25
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Spero Therapeutics Business Overview & Revenue Model
Company Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases withi...
Spero Therapeutics Earnings Call Summary
The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Spero said the key near‑term financial and development guidance is anchored by a $105.0M nondilutive, nonrecourse royalty financing (special‑purpose subsidiary issued $105M senior secured notes, 10% annual interest, 9‑year maturity, principal & interest payable quarterly from GSK Utebzi milestones/royalties; after repayment Spero retains 35% of additional GSK proceeds) and an exclusive SP001 license with Innovent with an estimated $1.1B total contingent value; cash & cash equivalents were $50.8M as of June 30 (pre‑financing) and, together with the financing, are expected to fund the $35M nonrefundable Innovent upfront plus operating and capex into the second half of 2029 (cash runway updated to 2H‑2029). Operational milestones include a Phase II IgG4‑RD trial planned to begin in Q2‑2027 (open‑label, 6 monthly doses, two dosing arms, up to ~15 patients per arm, i.e., ~30 patients total) and Utebzi availability in the U.S. in 2H‑2026; reported Q2‑2026 P&L metrics were net loss $9.6M (diluted loss per share $0.16) vs $1.7M ($0.03) in Q2‑2025, revenue $0 (vs $14.2M), R&D $3.4M (vs $10.7M) and G&A $6.5M (vs $5.9M).
Spero Therapeutics Risk Analysis
Spero Therapeutics disclosed 65 risk factors in its most recent earnings report. Spero Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSpero Therapeutics Peers Comparison
Overall Rating
INO55Neutral
NNVC46Neutral
COCP45Neutral
MCRB44Neutral
PDSB44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| INO | 55Neutral | $276.28M | -1.82 | 0.84% | ― | 63.93% | 68.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NNVC | 46Neutral | $35.22M | -3.23 | -91.11% | ― | ― | 35.47% |
| COCP | 45Neutral | $19.65M | -1.26 | -207.47% | ― | ― | 38.55% |
| MCRB | 44Neutral | $15.29M | -0.28 | -148.34% | ― | 505.41% | -889.29% |
| PDSB | 44Neutral | $107.11M | -1.56 | -708.20% | ― | ― | 30.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:2HA | Spero Therapeutics | 0.90 | -1.15 | -56.19% | |
| INO | Inovio Pharmaceuticals | 1.46 | -0.52 | -26.26% | |
| NNVC | NanoViricides Inc | 1.35 | -0.11 | -7.53% | |
| MCRB | Seres Therapeutics Inc. | 1.41 | -20.23 | -93.48% | |
| PDSB | Pds Biotechnology | 0.98 | 0.20 | 26.13% | |
| COCP | Cocrystal Pharma | 0.99 | -0.03 | -2.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.